| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | IPA-3 | GDSC1000 | pan-cancer | AAC | 0.0069 | 0.8 |
| mRNA | OSI-027 | GDSC1000 | pan-cancer | AAC | 0.0065 | 0.8 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | darinaparsin | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | MP470 | GDSC1000 | pan-cancer | AAC | 0.007 | 0.8 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | -0.0067 | 0.8 |
| mRNA | GDC-0941 | CTRPv2 | pan-cancer | AAC | 0.007 | 0.8 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0062 | 0.8 |
| mRNA | KX2-391 | CTRPv2 | pan-cancer | AAC | 0.0061 | 0.8 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.015 | 0.8 |